169 related articles for article (PubMed ID: 16823043)
1. Structure of the angiogenesis inhibitor ovalicin bound to its noncognate target, human Type 1 methionine aminopeptidase.
Addlagatta A; Matthews BW
Protein Sci; 2006 Aug; 15(8):1842-8. PubMed ID: 16823043
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for the functional differences between type I and type II human methionine aminopeptidases.
Addlagatta A; Hu X; Liu JO; Matthews BW
Biochemistry; 2005 Nov; 44(45):14741-9. PubMed ID: 16274222
[TBL] [Abstract][Full Text] [Related]
3. Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2.
Griffith EC; Su Z; Niwayama S; Ramsay CA; Chang YH; Liu JO
Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15183-8. PubMed ID: 9860943
[TBL] [Abstract][Full Text] [Related]
4. A single amino acid residue defines the difference in ovalicin sensitivity between type I and II methionine aminopeptidases.
Brdlik CM; Crews CM
J Biol Chem; 2004 Mar; 279(10):9475-80. PubMed ID: 14676204
[TBL] [Abstract][Full Text] [Related]
5. A single amino acid difference between archaeal and human type 2 methionine aminopeptidases differentiates their affinity towards ovalicin.
Bala S; Reddi B; Addlagatta A
Biochim Biophys Acta Proteins Proteom; 2023 Feb; 1871(2):140881. PubMed ID: 36396098
[TBL] [Abstract][Full Text] [Related]
6. Structure of human methionine aminopeptidase-2 complexed with fumagillin.
Liu S; Widom J; Kemp CW; Crews CM; Clardy J
Science; 1998 Nov; 282(5392):1324-7. PubMed ID: 9812898
[TBL] [Abstract][Full Text] [Related]
7. The anti-angiogenic agent fumagillin covalently modifies a conserved active-site histidine in the Escherichia coli methionine aminopeptidase.
Lowther WT; McMillen DA; Orville AM; Matthews BW
Proc Natl Acad Sci U S A; 1998 Oct; 95(21):12153-7. PubMed ID: 9770455
[TBL] [Abstract][Full Text] [Related]
8. Discovery of natural product ovalicin sensitive type 1 methionine aminopeptidases: molecular and structural basis.
Pillalamarri V; Arya T; Haque N; Bala SC; Marapaka AK; Addlagatta A
Biochem J; 2019 Mar; 476(6):991-1003. PubMed ID: 30837307
[TBL] [Abstract][Full Text] [Related]
9. Understanding the selectivity of fumagillin for the methionine aminopeptidase type II.
Klein CD; Folkers G
Oncol Res; 2003; 13(12):513-20. PubMed ID: 12899241
[TBL] [Abstract][Full Text] [Related]
10. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2.
Sin N; Meng L; Wang MQ; Wen JJ; Bornmann WG; Crews CM
Proc Natl Acad Sci U S A; 1997 Jun; 94(12):6099-103. PubMed ID: 9177176
[TBL] [Abstract][Full Text] [Related]
11. Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin.
Griffith EC; Su Z; Turk BE; Chen S; Chang YH; Wu Z; Biemann K; Liu JO
Chem Biol; 1997 Jun; 4(6):461-71. PubMed ID: 9224570
[TBL] [Abstract][Full Text] [Related]
12. Methionine AminoPeptidase Type-2 Inhibitors Targeting Angiogenesis.
Ehlers T; Furness S; Robinson TP; Zhong HA; Goldsmith D; Aribser J; Bowen JP
Curr Top Med Chem; 2016; 16(13):1478-88. PubMed ID: 26369821
[TBL] [Abstract][Full Text] [Related]
13. Structure and function of the methionine aminopeptidases.
Lowther WT; Matthews BW
Biochim Biophys Acta; 2000 Mar; 1477(1-2):157-67. PubMed ID: 10708856
[TBL] [Abstract][Full Text] [Related]
14. Homology modeling and calculation of the cobalt cluster charges of the Encephazlitozoon cuniculi methionine aminopeptidase, a potential target for drug design.
Bontems F; le Floch P; Duffieux F; Biderre C; Peyret P; Lallemand JY
Biophys Chem; 2003 Aug; 105(1):29-43. PubMed ID: 12932577
[TBL] [Abstract][Full Text] [Related]
15. The 1.15A crystal structure of the Staphylococcus aureus methionyl-aminopeptidase and complexes with triazole based inhibitors.
Oefner C; Douangamath A; D'Arcy A; Häfeli S; Mareque D; Mac Sweeney A; Padilla J; Pierau S; Schulz H; Thormann M; Wadman S; Dale GE
J Mol Biol; 2003 Sep; 332(1):13-21. PubMed ID: 12946343
[TBL] [Abstract][Full Text] [Related]
16. Proteomics-based target identification: bengamides as a new class of methionine aminopeptidase inhibitors.
Towbin H; Bair KW; DeCaprio JA; Eck MJ; Kim S; Kinder FR; Morollo A; Mueller DR; Schindler P; Song HK; van Oostrum J; Versace RW; Voshol H; Wood J; Zabludoff S; Phillips PE
J Biol Chem; 2003 Dec; 278(52):52964-71. PubMed ID: 14534293
[TBL] [Abstract][Full Text] [Related]
17. Identification of the molecular basis of inhibitor selectivity between the human and streptococcal type I methionine aminopeptidases.
Arya T; Reddi R; Kishor C; Ganji RJ; Bhukya S; Gumpena R; McGowan S; Drag M; Addlagatta A
J Med Chem; 2015 Mar; 58(5):2350-7. PubMed ID: 25699713
[TBL] [Abstract][Full Text] [Related]
18. Structure of a microsporidian methionine aminopeptidase type 2 complexed with fumagillin and TNP-470.
Alvarado JJ; Nemkal A; Sauder JM; Russell M; Akiyoshi DE; Shi W; Almo SC; Weiss LM
Mol Biochem Parasitol; 2009 Dec; 168(2):158-67. PubMed ID: 19660503
[TBL] [Abstract][Full Text] [Related]
19. Methionine aminopeptidases and angiogenesis.
Bradshaw RA; Yi E
Essays Biochem; 2002; 38():65-78. PubMed ID: 12463162
[TBL] [Abstract][Full Text] [Related]
20. Identification of an SH3-binding motif in a new class of methionine aminopeptidases from Mycobacterium tuberculosis suggests a mode of interaction with the ribosome.
Addlagatta A; Quillin ML; Omotoso O; Liu JO; Matthews BW
Biochemistry; 2005 May; 44(19):7166-74. PubMed ID: 15882055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
